Gilead Sciences vs Regeneron Pharmaceuticals
Gilead Sciences is the larger business, with $29.44bn of revenue in fiscal 2025 against $14.34bn for Regeneron Pharmaceuticals (2.1 times as much). Gilead Sciences grew faster (2.4% against 1.0%). Regeneron Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 31.4% against 28.9%. Regeneron Pharmaceuticals carries less debt relative to equity (6.4% against 109.8%).
| Latest fiscal year | Gilead SciencesGILD, 2025 | Regeneron PharmaceuticalsREGN, 2025 |
|---|---|---|
| Revenue | $29.44bn | $14.34bn |
| Revenue growth | 2.4% | 1.0% |
| Net income | $8.51bn | $4.50bn |
| Operating margin | 34.0% | 24.9% |
| Net margin | 28.9% | 31.4% |
| Return on equity | 40.5% | 14.9% |
| Free cash flow | $9.46bn | $4.08bn |
| Cash | $7.56bn | $3.12bn |
| Total debt | $24.94bn | $1.99bn |
| Debt to equity | 109.8% | 6.4% |
| Dividend per share | $3.16 | — |
| Dividend yield | 1.9% | 0.4% |
| Share buybacks | $1.92bn | $3.44bn |
| Employees | 17,000 | 15,410 |
| Market value | $208.99bn | $102.62bn |
| Price vs our value range | Within our value range | Within our value range |
| Moat score | 79 (Strong) | 86 (Strong) |
| Insider trades, 12 months | 0 buys, 83 sales | 0 buys, 105 sales |